AbCellera Biologics (AbCellera Biologics) Total Inventories : $0.74 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is AbCellera Biologics Total Inventories?

AbCellera Biologics's total inventories for the quarter that ended in Mar. 2024 was $0.74 Mil. AbCellera Biologics's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $0.92 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. AbCellera Biologics's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $1.33.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year. AbCellera Biologics's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.00.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. AbCellera Biologics's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.09.

AbCellera Biologics Total Inventories Historical Data

The historical data trend for AbCellera Biologics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics Total Inventories Chart

AbCellera Biologics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

0.16

1.41

1.67

1.53

1.11

AbCellera Biologics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Inventories	Get a 7-Day Free Trial															1.45	1.45	1.19	1.11	0.74

AbCellera Biologics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

AbCellera Biologics (NAS:ABCL) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

AbCellera Biologics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

	Net-Net Working Capital Per Share (Q: Mar. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(698.023	+	0.75 * 34.419	+	0.5 * 0.738	-	333.183
-	0	-	0)	/	293.621
=	1.33

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

AbCellera Biologics's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	0.9225	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

AbCellera Biologics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	0	/	0.9225
	=	0.00

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

AbCellera Biologics's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	0.9225	/	9.954
	=	0.09

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

AbCellera Biologics Total Inventories Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

AbCellera Biologics (AbCellera Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (NAS:ABCL) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

8QQ:Germany

Address

2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1

Website

https://www.abcellera.com

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Executives

John S. Montalbano	director	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Michael R Hayden	director	C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Veronique Lecault	director, officer: Chief Operating Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Thermopylae Holdings Ltd.	10 percent owner	2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Andrew Booth	officer: Chief Financial Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Andrew Lo	director	C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
John Hamer	director, 10 percent owner	PO BOX 14528, RESEARCH TRIANGLE PARK NC 27709-4528
Ester Falconer	officer: Chief Technology Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Hansen Carl L. G.	director, 10 percent owner, officer: Chief Executive Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Tryn Stimart	officer: Chief Legal Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Peter Thiel	director	9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069
Dcvc Bio, L.p.	10 percent owner	317 UNIVERSITY AVENUE, SUITE 200, PALO ALTO CA 94301
Dcvc Bio Gp, Llc	10 percent owner	270 UNIVERSITY AVENUE, PALO ALTO CA 94301
Zachary Bogue	10 percent owner	270 UNIVERSITY AVENUE, PALO ALTO CA 94301
Matthew Ocko	10 percent owner	270 UNIVERSITY AVENUE, PALO ALTO CA 94301